KeyBanc initiated coverage of Rapid Micro Biosystems (RPID) with an Overweight rating and $8 price target The analyst believes Rapid Micro’s Microbial Growth Direct System is “changing the paradigm” in biological manufacturing quality control. The system is more accurate and provides digital results in three to five days versus manual methods in 5-14 days, the analyst tells investors in a research note. KeyBanc says Rapid Micro is gaining wide adoption in the biopharmaceutical industry that will increase sales visibility and improve margins.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPID:
- Rapid Micro Biosystems Reports Record Revenue Growth
- Closing Bell Movers: Vericel down 11% after Q4 pre-announcement
- Rapid Micro Biosystems raises FY24 revenue view to $28.1M from at least $27M
- Rapid Micro Biosystems announces QC solution collaboration with Lonza
- Rapid Micro Biosystems reports preliminary Q4 revenue $8.2M, consensus $7.6M